Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The LuxN-type histidine kinase autoinducer-1 sensor is a transmembrane hybrid histidine kinase that serves as the primary receptor for Autoinducer-1 (AI-1), specifically N-(3-hydroxybutanoyl)-L-homoserine lactone, in Vibrio harveyi and related bacterial species (Jung et al., 2007; Swem et al., 2008). It is a central component of the quorum sensing (QS) system, a communication mechanism that allows bacteria to monitor their population density and coordinate collective behaviors (Waters and Bassler, 2005). At low cell densities, LuxN functions as a kinase, initiating a phosphorylation cascade through LuxU to the response regulator LuxO, which represses the expression of master regulators like LuxR (Freeman and Bassler, 1999; Timmen et al., 2006). Upon binding AI-1 at high cell densities, LuxN switches to a phosphatase state, leading to the dephosphorylation of LuxO and the subsequent activation of LuxR-mediated gene expression (Swem et al., 2008). This regulatory switch controls critical processes such as bioluminescence, biofilm formation, and the production of virulence factors, including proteases and type III secretion systems (Henke and Bassler, 2004). As a therapeutic target, LuxN is being explored for the development of anti-virulence agents that disrupt bacterial communication to attenuate infection without killing the bacteria directly (Swem et al., 2009). Small-molecule antagonists, such as the AHL analog C450-0730, have been identified that competitively inhibit AI-1 binding and lock the receptor in a specific signaling state (Swem et al., 2009). Targeting LuxN offers a potential strategy to combat antibiotic-resistant pathogens by reducing their pathogenicity and enhancing the efficacy of the host immune response (Fleitas Martínez et al., 2019).
Competitive antagonism of the autoinducer-1 binding site, which modulates the balance between the receptor's kinase and phosphatase activities to disrupt quorum sensing-regulated gene expression.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LuxN-type histidine kinase autoinducer-1 sensor (LuxN).